May 25, 2005 ­ Amarin Corporation plc (NASDAQSC: AMRN) today announced that it has completed its previously announced registered direct offering with institutional and other accredited investors for gross proceeds of $17.8 million. The financing is intended to strengthen Amarin´s balance sheet and to provide funding for clinical trials. Miraxion, Amarin´s lead development compound, is in phase III development for Huntington´s disease and in phase II development for treatment of unresponsive depression. Palladium Capital Advisors acted as a consultant to ProSeed Capital Holdings, which served as placement agent for Amarin Corp.